New Two-Target cancer drug enters first human trials
NCT ID NCT07166601
Summary
This is the first study in people to test a new drug called M0324 for advanced solid tumors. The main goal is to find a safe dose and see how the body handles the drug. Researchers will test M0324 alone, with an immunotherapy drug, and with chemotherapy in about 77 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai
NOT_YET_RECRUITINGNew York, New York, 10029, United States
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78249, United States
-
National Cancer Center Hospital
RECRUITINGChūōku, Japan
-
Princess Margaret Cancer Centre
NOT_YET_RECRUITINGToronto, Canada
-
Yale University School of Medicine
RECRUITINGNew Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.